Scientific leaders in CAR-CIK technology

Conducted first-in-man CAR-CIK clinical trial

Andrea Biondi, MD

Professor of Pediatrics

University of Milano-Bicocca
Director, Department of Pediatrics
European Reference Network (ERN) PaedCan, EuroBloodNet,MetabERN.
Fondazione MBBM/Ospedale San Gerardo
Via Pergolesi, 33
20900 Monza (IT)

Director of the Pediatric Department, Full Professor of Pediatrics and Director of the Pediatric Residency Program at the University of Milano-Bicocca, Monza – Italy. Scientific Director of the “M.Tettamanti” Research Center for leukemic and hematological diseases of children, and of “S. Verri” Cellular and Gene Therapy Laboratory. since April 2016 Chairman of the International-BFM Study Group.

His research focuses on the molecular characterization of pediatric leukemia, either in terms of cloning and identification of new genes as well as in the use of molecular tools in clinical studies leading to the standardization of molecular technique for the assessment of Minimal residual Disease in childhood ALL. Since 2007 he has promoted several innovative pre-clinical and clinical research projects in the field of cellular and gene therapy for childhood ALL. One project specifically resulted in the filing of a new patent for non-viral transduction method of Chimeric-Antigen-Receptor genes in CIK cells.

Prof. Andrea Biondi has published more than 600 manuscripts in peer-reviewed journals such as Lancet, Lancet Oncology, Lancet Haematology, Journal of Clinical Oncology , Blood and Leukemia for which he routinely serves as referee.

Alessandro Rambaldi, MD

Professor of Hematology of the Department of Oncology and Hematology

Department of Hematology-Oncology, University of Milan and Ospedale Papa Giovanni XXIII, Bergamo
Piazza OMS, 1
24127 Bergamo, Italy

Alessandro Rambaldi, MD, is Full Professor of Hematology of the Department of Oncology and Hematology at the University of Milan, Italy. Since 2006 he is the Director of the Hematology and Bone Marrow Transplant Unit at the Ospedale Papa Giovanni XXIII, Bergamo, Italy. 

His scientific interest ranges from translational research to academic clinical trials in which he pioneered the integration of molecular evaluation of minimal residual disease in the treatment strategy of adult patients with acute lymphoblastic leukemia and non-Hodgkin’s lymphomas. He also led several trials in the field of acute leukemia, lymphomas chronic myeloproliferative neoplasms and allogeneic stem cell transplantation. A current special research interest is the development of innovative cellular therapies for the treatment of leukemia relapse after allogeneic stem cell transplantation. 

Prof. Alessandro Rambaldi has published more than 570 manuscripts in peer-reviewed journals such as Lancet Oncology, Journal of Clinical Oncology (member of the Editorial Board), Blood and Leukemia for which he routinely serves as referee.

Global leaders from MSK

Integrating new technologies into CAR-CIK platform

David Scheinberg, MD, PhD

Chair, Molecular Pharmacology Program, MSK;
Director, Experimental Therapeutics Center; Vincent Astor Chair

Renier J. Brentjens, MD, PhD

Deputy Director and Chair of Medicine, Roswell Park Comprehensive Cancer Center (formerly at MSKCC), Scientific cofounder of Juno

Derek Tan, PhD

Chair, Chemical Biology Program, MSK: Director and Professor, Tri-Institutional PhD Program in Chemical Biology